Log In
Print
BCIQ
Print
Print this Print this
 

vesigenurtacel-L (HS-410)

  Manage Alerts
Collapse Summary General Information
Company Heat Biologics Inc.
DescriptionBladder cancer cell line genetically modified using Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete bladder cancer antigens bound to a heat shock 90 kDa protein beta 1 (Hsp90B1; GP96; GRP94) adjuvant
Molecular Target Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationBladder cancer
Indication DetailsTreat non-muscle invasive bladder cancer
Regulatory Designation

U.S. - Fast Track (Treat non-muscle invasive bladder cancer)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today